SLS | tickerfilter.com

Fundamental analysis

Profitability 8%

Dept financing 13%

Liquidity 38%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-3.41%

1 Month

-0.01%

3 Months

-26.40%

6 Months

-15.60%

1 Year

76.48%

2 Year

-67.61%

Key data

Stock price

$0.92

P/E Ratio

0.00

DAY RANGE

$0.87 - $0.95

EPS

-$2.13

52 WEEK RANGE

$0.52 - $1.72

52 WEEK CHANGE

$76.48

MARKET CAP

80.416 M

YIELD

N/A

SHARES OUTSTANDING

64.332 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.56

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,680,375

AVERAGE 30 VOLUME

$1,345,297

Company detail

CEO: Angelos M. Stergiou
Region: US
Website: sellaslifesciences.com
Employees: 10
IPO year: 2008

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

SELLAS Life Sciences Group, Inc. focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapy that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials. The company was founded in 2012 and is headquartered in New York, New York.

SLS - SELLAS Life Sciences Group, Inc.